Business Wire

 Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases

Share

Knopp Biosciences LLC today reports data demonstrating that compound subgroups from its proprietary library of potassium-channel modulators selectively target Kv7 channel subtypes associated with a wide range of neurological and smooth muscle diseases. The data is being presented at the International Kv7 Channels Symposium 2019 in Naples, Italy.

Presentation Title: The Re-emergence of Kv7 Drug Discovery
Presenter: Michael Bozik, M.D., CEO, Knopp Biosciences
Date & Time: September 13, 4:35 pm CEST

Michael Bozik, M.D., Chief Executive Officer of Knopp, will present the data derived from the Company’s proprietary library of more than 3,000 novel compounds directed to modulating the Kv7 channel, which regulates the flow of potassium ions across cell membranes. The data demonstrate that specific subgroups of Kv7 compounds selectively modulate different Kv7 channel subtypes across ranges of channel activation and inhibition, enabling selection of compounds capable of targeting neurological disorders associated principally with Kv7.2/7.3 channels and others associated principally with Kv7.4 channels.

“By characterizing a custom library of Kv7 modulators for activity and specificity, we have shown evidence of the potential to develop targeted treatments for diverse diseases of the central nervous system and smooth muscle,” said Dr. Bozik. “Accordingly, we believe our Kv7 library represents a precision tool-set for investigating Kv7 pharmacology across a wide range of therapeutic areas with high unmet need.”

Engineered cell lines expressing the channel subtypes Kv7.2/7.3, Kv7.4, Kv7.3/7.5, and Kv7.1/KCNE1 were used in a screening format to characterize compound activity. A thallium flux assay was the primary screen to determine effective concentration values (EC50) for Kv7.2/7.3 activity and to rank-order compounds. Active compounds were then counter-screened against other Kv7 cell lines. The QPatch HTx automated patch-clamp system provided a confirmatory functional assay to further characterize the electrophysiology properties of these novel compounds.

Knopp’s lead Kv7 modulator, KB-3061, is in preclinical development for KCNQ2 epileptic encephalopathy, a rare neonatal disease characterized by seizures beginning in the first days of life and by significant developmental delay.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for neurological and immunological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Media inquiries:
James Heins
james.heins@icrinc.com
203-682-8251

Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Generation in Cryptocurrency Mining by BitHarp23.9.2019 17:45:00 EESTPress release

Lyre Miner and Harp Miner, two recently released cryptocurrency mining rigs from www.BitHarp.com ( BitHarp Group Limited ), are quickly turning out to be gamechangers in the global crypto market. Within their short lifespan, these two products have shown promises of revolutionizing this thriving industry by offering superfast ROI for seasoned miners as well as beginners looking to try their hand at crypto mining. The ability of Lyre Miner and Harp Miner to generate quick return on investment can be attributed to the high hash rates of the products. The term hash rate may be referred to as the speed at which a given mining machine operates. A higher hash rate increases the opportunity of a miner to find the next block and receive the reward. Making things even better for the miners, Lyre Miner and Harp Miner have significantly low energy consumptions of 600W and 2400 W respectively. The hash rate powers offered by Lyre Miner and Harp Miner are mentioned below at a glance. Lyre Miner: 33

Jabil Photonics to Demonstrate Coherent SiP based 100G/200G CFP2-DCO Product at ECOC 201923.9.2019 15:48:00 EESTPress release

Jabil (NYSE: JBL) today announced that its Photonics business unit, a leading provider of customized end-to-end design, manufacturing and test solutions for optical communication products, will be demonstrating its coherent 100G/200G CFP2-DCO module this week at the ECOC Exhibition (Hall 4, Booth 498) in Dublin, Ireland. Jabil’s CFP2-DCO is a hot-pluggable module designed to support single-wavelength data coherent transmission at 100Gbps using DP-QPSK and 200Gbps using DP-16QAM modulations. The CFP2-DCO is designed for DWDM networks ranging from metro and data-center interconnect (DCI) to long-haul applications, as well as 100Gbps point-to-point (P2P) coherent solutions for unamplified links in 5G and cable access networks up to 80km. Powered by Elenion Technologies’ next generation Silicon Photonics (SiP) coherent engine, the Jabil Photonics CFP2-DCO sets a new standard for price-performance. The module incorporates an ultra-narrow linewidth external cavity micro-ITLA laser with gridl

CE China 2019: Suning Launches New Biu Products23.9.2019 15:43:00 EESTPress release

Premiere at CE China: The Chinese retail giant Suning, strategic partner of CE China, has seized the opportunity to present eight new products of its Biu product line for smart home appliances at the CE China in Guangzhou. On this occasion, fans of Biu were invited to the first ever Biu fan festival to attend the launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005490/en/ Suning Launches New Biu Products at CE China 2019 (Graphic: Business Wire) Behind closed curtains, selected Biu-fans were the first to learn about the premieres of intelligent smart home products at the booth of Suning on the trade show. Among others, Suning presented the new Biu air conditioner as a “pro version”, the "Little Dolphin" electric water heater and the "Little Seashells" gas water heater. Suning representatives also showed, how the different devices connect with each other. According to Suning, Biu will continue to focus on smart pr

FLIR Introduces M300 Series Marine Cameras23.9.2019 15:00:00 EESTPress release

FLIR Systems (NASDAQ: FLIR) today announced the FLIR M300 Series, a new generation of maritime thermal cameras delivering advanced awareness-enhancing technologies, safer navigation, and seamless integration with onboard boat systems. FLIR M300 Series cameras are designed for the most demanding professional mariners and first responders who operate in the harshest marine environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005214/en/ FLIR M300 Series thermal imaging cameras for professional mariners and first responders provide safer navigation and increased situational awareness (Photo: Business Wire) The successor to FLIR’s industry-leading M-Series of maritime cameras, the next generation M300 Series consists of five models featuring rugged and robust new pan and tilt housings – four models with the FLIR Boson™ resolution thermal camera cores, plus a visible-only, high-definition (HD) model. The series is hi

Mary Kay, in Collaboration With UN Agencies, Launches Women’s Entrepreneurship Accelerator23.9.2019 15:00:00 EESTPress release

Today, Mary Kay Inc., a leading advocate of women’s empowerment and entrepreneurship, announced the Women’s Entrepreneurship Accelerator, a multi-partner initiative designed to inspire, educate, and empower women entrepreneurs around the world. With no qualifying barriers to participate, the ground-breaking initiative is a strategic collaboration developed in consultation with six United Nations agencies: UN Women, United Nations Office for Partnerships (UNOP), International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), and the United Nations Development Programme (UNDP). The Accelerator will offer a guided digital curriculum supplemented by on-the-ground training and mentorship. In addition, it will serve as an advocacy platform to eliminate entrepreneurial roadblocks for women, ranging from digital literacy to legal reform—enabling women to fully participate in the growth of their local and national economies. The Accelerator will support glob

Western Union Expands Global Real-time Payment Capabilities for Millions of Consumers and Business Accounts23.9.2019 15:00:00 EESTPress release

Sibos Conference – Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, today announced availability of its real-time cross-border platform to accelerate international consumer, consumer-to-business and business-to-consumer payments to eligible accounts, cards and digital wallets. The announcement marks an expansion of Western Union’s unique ability to leverage its core assets – including global settlement capabilities, network, compliance and technology systems – to enable international cross-border payments in minutes across multiple currencies. Globally recognized for daily cross-currency management and settlement via its vast retail network across 20,000 corridors or pairs of countries for consumers in local currency, the company’s expanded money in minutes platform will now power next-generation cross-border payment experiences for consumers and businesses across a multitude of sectors. “This is a prime example of how the global reach, inter-connected

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom